GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (HAM:DMP) » Definitions » Price-to-Owner-Earnings

Dermapharm Holding SE (HAM:DMP) Price-to-Owner-Earnings : 17.05 (As of Jun. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE Price-to-Owner-Earnings?

As of today (2024-06-22), Dermapharm Holding SE's share price is €36.15. Dermapharm Holding SE's Owner Earnings per Share (TTM) ended in Mar. 2024 was €2.12. It's Price-to-Owner-Earnings for today is 17.05.


The historical rank and industry rank for Dermapharm Holding SE's Price-to-Owner-Earnings or its related term are showing as below:

HAM:DMP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.43   Med: 15.91   Max: 47.19
Current: 16.94

During the past 11 years, the highest Price-to-Owner-Earnings of Dermapharm Holding SE was 47.19. The lowest was 9.43. And the median was 15.91.


HAM:DMP's Price-to-Owner-Earnings is ranked better than
66.43% of 426 companies
in the Drug Manufacturers industry
Industry Median: 24.595 vs HAM:DMP: 16.94

As of today (2024-06-22), Dermapharm Holding SE's share price is €36.15. Dermapharm Holding SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €1.05. Therefore, Dermapharm Holding SE's PE Ratio for today is 34.43.

As of today (2024-06-22), Dermapharm Holding SE's share price is €36.15. Dermapharm Holding SE's EPS without NRI for the trailing twelve months (TTM) ended in was €1.05. Therefore, Dermapharm Holding SE's PE Ratio without NRI for today is 34.43.

During the past 11 years, Dermapharm Holding SE's highest PE Ratio without NRI was 42.90. The lowest was 8.74. And the median was 22.11.


Dermapharm Holding SE Price-to-Owner-Earnings Historical Data

The historical data trend for Dermapharm Holding SE's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Price-to-Owner-Earnings Chart

Dermapharm Holding SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 39.79 27.16 10.60 16.49

Dermapharm Holding SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.42 12.40 12.52 16.49 15.52

Competitive Comparison of Dermapharm Holding SE's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Price-to-Owner-Earnings falls into.



Dermapharm Holding SE Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Dermapharm Holding SE's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=36.15/2.12
=17.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermapharm Holding SE  (HAM:DMP) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Dermapharm Holding SE Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE (HAM:DMP) Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs and natural remedies. Its portfolio of products includes cosmetics, nutritional supplements and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals and cosmetics products. Parallel import brands business operates under the AxiCorp brand.

Dermapharm Holding SE (HAM:DMP) Headlines

No Headlines